<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01223898</url>
  </required_header>
  <id_info>
    <org_study_id>CAMN107A2128</org_study_id>
    <secondary_id>2009-009425-28</secondary_id>
    <nct_id>NCT01223898</nct_id>
  </id_info>
  <brief_title>To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of Nilotinib</brief_title>
  <official_title>An Open-label, Two-period, Fixed-sequence Study to Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics of Midazolam in CML Patients Who Are Resistant and/or Intolerant Against at Least One Prior Therapy With a BCR-ABL Tyrosine Kinase Inhibitor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will evaluate the effects of multiple doses of nilotinib on the pharmacokinetics&#xD;
      and metabolism of midazolam (as a sensitive CYP3A probe) in CML patients. The following&#xD;
      extension study does evaluate the safety of nilotinib.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluate the effects of multiple doses of nilotinib on the pharmacokinetics and metabolism of midazolam in CML patients.</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>evaluate the safety and tolerability of multiple doses of nilotinib when midazolam is co-administered orally in CML patients.</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of safety of nilotinib during the extension study phase.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Nilotinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tasigna</intervention_name>
    <arm_group_label>Nilotinib</arm_group_label>
    <other_name>AMN107</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with a cytopathologically confirmed diagnosis of Ph+ CML or Philadelphia&#xD;
             chromosome- negative (Ph-) CML patients in accelerated or chronic phase who are&#xD;
             resistant and/or intolerant against at least one prior therapy with a BCR-ABL tyrosine&#xD;
             kinase inhibitor&#xD;
&#xD;
          2. Female or male ≥ 18 years of age&#xD;
&#xD;
          3. Patients who are nilotinib naïve at study entry, e.g. did not receive any nilotinib&#xD;
             treatment prior to study&#xD;
&#xD;
          4. WHO Performance Status of ≤ 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known cytopathologically confirmed CNS infiltration (in absence of suspicion of CNS&#xD;
             involvement, lumbar puncture not required).&#xD;
&#xD;
          2. Impaired cardiac function&#xD;
&#xD;
          3. History of acute pancreatitis within 1 year of study entry or past medical history of&#xD;
             chronic pancreatitis.&#xD;
&#xD;
          4. Patients actively receiving therapy with the prohibited co-medications (CYP3A4&#xD;
             inhibitors or inducers, or CYP2C inducers)&#xD;
&#xD;
          5. Patients who are currently receiving treatment with any medications that have the&#xD;
             potential to prolong the QT interval&#xD;
&#xD;
          6. Treatment with immunotherapy or chemotherapy within 3 days (6 weeks for nitrosurea or&#xD;
             mitomycin-C) prior to Day 1 or who have not recovered from side effects of such&#xD;
             therapy.&#xD;
&#xD;
          7. Treatment with imatinib within 1 week prior to Day 1 or who have not recovered from&#xD;
             side effects of such therapy.&#xD;
&#xD;
          8. Patients who have hypersensitivity to midazolam or related compounds&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt/M</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <link>
    <url>https://www.novctrd.com/ctrdweb/trialresult/trialresults/pdf?trialResultId=12976</url>
    <description>Results for CAMN107A2128 can be found on the Novartis Clinical Trial Results Website</description>
  </link>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>October 18, 2010</study_first_submitted>
  <study_first_submitted_qc>October 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2010</study_first_posted>
  <last_update_submitted>December 6, 2020</last_update_submitted>
  <last_update_submitted_qc>December 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CML,</keyword>
  <keyword>nilotinib,</keyword>
  <keyword>midazolam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

